Interestingly, new agents in prostate cancer with specific effects on bone like cabozantinib (XL184) [80] and dasatinib [81], which acted as a novel receptor tyrosine kinase inhibitor, have also been investigated. The gene discussed is NTRK1; the disease is Familial prostate cancer.